Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis

Bandari, Daniel S.; Sternaman, Debora; Chan, Theodore; Prostko, Chris R; Sapir, Tamar

doi:10.18553/jmcp.2012.18.s9-b.1

Cited by 15 publications

(16 citation statements)

References 100 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of available disease-modifying therapies (DMTs) has grown substantially in the last decade, allowing for a more tailored approach to treatment. However, this abundance of options has made treatment selection more complex (Bandari, Sternaman, Chan, Prostko, & Sapir, 2012;Wiese, Suppiah, & O'Doherty, 2014).…”

Section: Introductionmentioning

confidence: 99%

Treatment and disease management of multiple sclerosis patients

Roman

Menning

2017

Journal of the American Association of Nurse Practitioners

View full text Add to dashboard Cite

Background and purpose This review discusses the role of the nurse practitioner (NP) in evaluating the clinical effects, potential side effects, and monitoring requirements for treatment options in multiple sclerosis (MS) and provides guidance on how to help patients understand these issues. Methods A literature search was conducted on PubMed to identify publications on monitoring and disease management of MS patients. Additional resources included drug information web sites and package inserts. Conclusions NPs play an active role in the management of MS patients via effective monitoring and communication throughout the patient's treatment regimen and disease course. In the shared decision‐making model of MS treatment, NPs ensure that patients understand the implications of their disease‐modifying therapies (DMTs). As patients move through treatments during the course of their disease, the importance of this role increases, and it is critical that NPs follow the guidelines in each medication's product label and take into account any potential lingering effects of prior medications. Implications for practice It is critical for NPs to promote patient adherence, to ensure that patients understand treatment side effects and monitoring requirements, and to take sequencing and reversibility implications of DMTs into account when making clinical decisions.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment and disease management of multiple sclerosis patients

Roman

Menning

2017

Journal of the American Association of Nurse Practitioners

View full text Add to dashboard Cite

show abstract

“…23,42,43 Results varied among agents and, although the data provide an indication of the overall benefits of these agents, head-to-head trials are necessary to allow comparison between the agents for the outcomes achieved.…”

Section: Efficacy Of Disease Modifying Therapymentioning

confidence: 99%

Informing Decisions to Improve the Continuum of Care in RRMS

2014

International Journal of MS Care

View full text Add to dashboard Cite

“…Recent articles regarding rheumatoid arthritis and multiple sclerosis treatment, for example, have highlighted paradigm shifts in disease management and the need for improvement in process metrics and outcomes metrics. 5,6 Such metrics will be critical to multidisciplinary disease-management models, bringing physicians, pharmacists, and other providers together in an organized treatment plan with established objectives. Clinical services from SP pharmacists can be a core component.…”

Section: Kp Pharmacy Service Versus Outsourced Dispensingmentioning

confidence: 99%

Specialty Pharmaceuticals Care Management in an Integrated Health Care Delivery System with Electronic Health Records

Monroe¹,

Chin²

2013

JMCP

View full text Add to dashboard Cite

SUMMARYThe specialty pharmaceuticals market is expanding more rapidly than the traditional pharmaceuticals market. Specialty pharmacy operations have evolved to deliver selected medications and associated clinical services. The growing role of specialty drugs requires new approaches to managing the use of these drugs. The focus, expectations, and emphasis in specialty drug management in an integrated health care delivery system such as Kaiser Permanente (KP) can vary as compared with more conventional health care systems.The KP Specialty Pharmacy (KP-SP) serves KP members across the United States. This descriptive account addresses the impetus for specialty drug management within KP, the use of tools such as an electronic health record (EHR) system and process management software, the KP-SP approach for specialty pharmacy services, and the emphasis on quality measurement of services provided.Kaiser Permanente's integrated system enables KP-SP pharmacists to coordinate the provision of specialty drugs while monitoring laboratory values, physician visits, and most other relevant elements of the patient's therapy. Process management software facilitates the counseling of patients, promotion of adherence, and interventions to resolve clinical, logistic, or pharmacy benefit issues. The integrated EHR affords KP-SP pharmacists advantages for care management that should become available to more health care systems with broadened adoption of EHRs. The KP-SP experience may help to establish models for clinical pharmacy services as health care systems and information systems become more integrated.

show abstract

Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis

Cited by 15 publications

References 100 publications

Treatment and disease management of multiple sclerosis patients

Treatment and disease management of multiple sclerosis patients

Informing Decisions to Improve the Continuum of Care in RRMS

Specialty Pharmaceuticals Care Management in an Integrated Health Care Delivery System with Electronic Health Records

Contact Info

Product

Resources

About